Summary
The effect of intraperitoneal instillations of interleukin-2 (IL-2) and/or lympokine-activated killer (LAK) cells on the ascites formation and the survival time was examined using nude mice as a model, with malignant ascites produced by intraperitoneal inoculation of human ovarian cancer cells derived from ascites of a patient with serous cystadenocarcinoma of the ovary. Twenty-eight days after tumor inoculation, all nude mice in the untreated group and in the group treated with spleen cells alone formed ascites. Two of ten nude mice treated with IL-2 alone after tumor inoculation survived without forming ascites during the experimental period. On the other hand, all nude mice treated with LAK cells alone had formed ascites 14 days after tumor inoculation. When LAK cells and IL-2 were combined, five of ten mice survived without forming ascites during the experimental period. The survival time of the group treated with IL-2 alone was significantly prolonged compared to the groups that received medium alone, spleen cells alone and LAK cells alone. When administration of LAK cells was followed by IL-2, the survival time was further prolonged.
Similar content being viewed by others
References
Cheever MA, Greenberg PD, Irle C, Thompson JA, Urdal DL, Mochizuki DY, Henney CS, Gillis S (1984) Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo. J Immunol 132:2259–2265
Ettinghausen SE, Lipford EH, Mulé JJ, Rosenberg SA (1985) Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transfered lymphokine-activated killer (LAK) cells. J Immunol 135:3623–3635
Hamilton TC, Ozols RF, Longo DL (1987) Biologic therapy for the treatment of malignant common epithelial tumors of the ovary. Cancer 60:1954–2063
Kikuchi Y, Hiramoto RN, Ghanta VK (1982) Mitogen response of peripheral blood and splenic lymphocytes and effect of 2-mercaptoethanol in tumor-bearing mice. Cancer Immunol Immunother 12:225–230
Kikuchi Y, Kizawa I, Oomori K, Kuki E, Kato K (1986) The inhibitory effect of tranexamic acid on human ovarian carcinoma cell grown in vitro and in vivo. Gynecol oncol 24:183–188
Kikuchi Y, Kizawa I, Oomori K, Miyauchi M, Kita T, Sugita M, Tenjin Y, Kato K (1987a) Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation. Cancer Res 47:592–596
Kikuchi Y, Oomori K, Kizawa I, Hirata J, Kita T, Miyauchi M, Kato K (1987b) Enhancement of antineoplastic effects of cisplatin by calmodulin antagonists in nude mice bearing human ovarian carcinoma. Cancer Res 47:6459–6461
Mazumdar A, Rosenberg SA (1984) Successful immunotherapy of natural killer-resistant established pulmonary melanome metastases by the intravenous adoptive trasfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 159:495–507
Mulé JJ, Shu S, Schwarz S, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225:1487–1489
Palladino MA, Welte K, Carroll AM, Oettgen HF (1984) Characterization of interleukin 2 (IL 2)-dependent cytotoxic T cell clones. V. Transfer of resistance to allografts and tumor grafts requires exogenous IL 2. Cell Immunol 86:299–307
Reynolds CW, Denn III AC, Barlozzari T, Wiltrout RH, Reichardt DA, Herbermann RB (1984) Natural killer activity in the rat. IV. Distribution of large granular lymphocytes (LGL) following intravenous and intraperitoneal transfer. Cell Immunol 86:371–380
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 patients with metastatic cancer. N Engl J Med 313:1485–1492
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Auis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 158 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897
West WH, Tauer KW, Yannell JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905
Additional information
Supported in part by a grant from the Special Scientific Research Program of the Defense Agency in Japan
Offprini requests to: Y. Kikuchi
Rights and permissions
About this article
Cite this article
Oomori, K., Kikuchi, Y., Miyauchi, M. et al. Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells. J Cancer Res Clin Oncol 115, 217–220 (1989). https://doi.org/10.1007/BF00391692
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00391692